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regional myocardial blood flow. Am Heart J 1990;120:808–18.
. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of
intracoronary adenosine as an adjunct to primary angioplasty in acute
myocardial infarction. Circulation 2000;101:2154–9.
MISTAD Trials: Possible
easons for Lack of Success
esults of the Acute Myocardial Infarction STudy of ADenosine
AMISTAD II) trial were recently reported by Ross et al. (1). As
n the AMISTAD I trial (2), most of the conclusions were at best
quivocal, although subgroup analysis each time suggested aden-
sine might be useful as an adjunct to reperfusion therapy in
ertain patients with acute myocardial infarction. Thus the hope
as raised that a more targeted trial might yield a significant
ifference between placebo and treatment groups. Although this
ossibility is real, we would like to offer an alternative hypothesis.
ontrary to the twice-repeated assertion by the investigators that
adenosine . . . has consistently provided myocardial protection
rom ischemic injury in animal models,” the ability of adenosine
dministered at or shortly before reperfusion to provide cardiopro-
ection against infarction is indeed quite controversial. There are
ertainly some studies which report that adenosine at reperfusion
an decrease infarct size in various animal models, and some of
hese experimental investigations are acknowledged by Ross et al.
1). However, it is notable that two of the references cited by the
esearchers to justify their conclusion have been misquoted. Yao
nd Gross (3) and Thornton et al. (4) found protection when
denosine or an adenosine agonist was used as a preconditioning
gent.
Furthermore, Thornton et al. (4) actually observed that when
6-(2-phenylisopropyl) adenosine (PIA) was infused at reperfu-
ion, it had no cardioprotective effect despite its effectiveness when
pplied as a pretreatment. Also, numerous other preclinical studies
ave been unable to document an effect of authentic adenosine
5–8) at reperfusion on infarct size. Therefore, it is possible that
oth the inability to demonstrate a significant effect of adenosine
t reperfusion in patients and the inconsistent preclinical results are
ecause adenosine given at reperfusion simply does not protect the
eart.
In the two AMISTAD trials it was reported that infarct size
as significantly diminished in those patients with anterior wall
yocardial infarction who were treated with adenosine. Although
his observation is potentially important and noteworthy, a tech-
ical limitation diminishes the significance of the data. It has been
ecognized for many years that a major determinant of infarct size
s the size of the region at risk. In fact, no experimental study of
nfarct size limitation would be accepted for publication if the size
f the risk region were not quantitated and used to normalize the
easurement of infarct size. It is recognized that it is difficult, but
ot impossible, to obtain these data in clinical studies because
cans must be recorded both before and after the intervention.
eliance on absolute infarct size as a percentage of the left
entricle—despite the many reasonable correlations between this
arameter and measures of ventricular function and clinical out-
ome, without normalization for the size of the region at risk—can
ield incorrect conclusions. And this difficulty is perhaps best
ighlighted by the very different measurements of infarction in
atients treated with placebo: 45% in the AMISTAD I study and
7% in the AMISTAD II study. dMichael V. Cohen, MD
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EPLY
e thank Drs. Cohen and Downey for their interest in our report
n treatment of anterior myocardial infarction with adenosine (1).
e do not agree that we misquoted Yao and Gross (2) and
hornton et al. (3) with respect to the cardioprotective effects of
denosine. The Thornton et al. study was cited, with others, in
tating that “adenosine has consistently provided myocardial pro-
ection from ischemic injury.” The Yao and Gross study (2)
upports the statement that “adenosine and adenosine agonists are
yocardial protectants.” We did not say that this protection was
pecifically related to the time of reperfusion, as implied. The
eduction in infarct size may have been related also to other
alutary effects of adenosine. In many patients the drug was on
oard during at least part of the time of coronary occlusion, and
hus it might have a protective effect during ischemia. Certainly, in
hose receiving thrombolytic therapy, there was a time lag between
dministration of the lytic and when reperfusion was complete.
hus, it is possible that adenosine played a protective role during
his time of continuing ischemia.
We do not agree that the difference in infarct size in the
MISTAD I and AMISTAD II studies somehow imputes the
eliability of the single-photon emission computed tomography
ata in the AMISTAD II study. The validity of SPECT infarct
